We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Leptin Associated with Poor Thyroid Cancer Prognosis

By LabMedica International staff writers
Posted on 14 Oct 2009
Leptin, a molecule linked with obesity, predicted poor prognosis from thyroid cancer in Saudi Arabia.

Scientists measured the level of leptin and its receptor in 536 human thyroid cancer samples. More...
They found that over expression of the leptin receptor was significantly associated with poor disease survival in 80% of the cases. Increased leptin receptor expression was linked with older age, larger tumor size, advanced stage, and metastasis. The scientists also demonstrated in laboratory in vitro experiments that leptin stimulated growth of thyroid cancer cells and prevented their death.

"Leptin receptor expression may be a useful molecular marker in predicting the level of aggression of Middle Eastern thyroid cancer that can help guide treatment options and follow-up care," said lead scientist Khawla S. Al-Kuraya, M.D., director of the research center at King Faisal Specialist Hospital and Research Center (Riyadh, Saudi Arabia). Leptin receptor status can be easily assessed with a fine needle biopsy, according to Dr. Al-Kuraya.

Whereas thyroid cancer is the eighth most common cancer among American women, it is the second most common in Saudi Arabian women. This high prevalence is seen in all Gulf Council countries, according to Dr. Al-Kuraya.

The data were presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting, held in Boston (USA) from Oct. 8-11, 2009.

Related Links:
King Faisal Specialist Hospital and Research Center




New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.